​Novo Nordisk A/S (NYSE:NVO) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December 12, Novo Nordisk A/S (NYSE:NVO) announced receiving a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use for a higher dosage of Wegovy. ​The positive opinion is based on improved weight loss results of around 20.7% at 72 weeks in people without diabetes. Management noted that the STEP UP and STEP UP T2D clinical trial program showed that one in three ob ...

Trump announces "Most Favored Nation" deals with nine drug companies, aiming to lower prices for US patients https://t.co/D9ylHIfi70 ...

Trump announces "Most Favored Nation" deals with nine drug companies, aiming to lower prices for US patients https://t.co/GvV1W9AhlL ...

Core Points - Merck has reached an agreement with the U.S. government aimed at expanding access to its medicines and reducing costs for American patients [1] Group 1 - The agreement is part of a broader initiative to enhance affordability and accessibility of healthcare for Americans [1] - Merck's collaboration with the government is expected to lead to significant reductions in the prices of certain medications [1] - This initiative aligns with ongoing efforts to address healthcare costs and improve patient access to essential treatments [1]

President Donald Trump signs an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC.Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump on Friday to voluntarily sell their medications for less, as his administration pushes to link the nation's drug prices to cheaper ones abroad.That includes Merck, Bristol Myers Squibb, Amgen ...

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to lower the price ...

The Trump administration signed deals with nine pharmaceutical companies on Friday, the latest in a series of pacts designed to lower drug prices in exchange for a reprieve from threatened tariffs on their products https://t.co/ixX5U0KWcJ ...

Core Insights - Viatris Inc. (VTRS) has announced four significant regulatory achievements in its pipeline, highlighting its R&D progress for 2025 and its commitment to advancing its portfolio globally [2][9]. Regulatory Approvals - The FDA has approved Viatris' octreotide acetate for injectable suspension, a generic version of Sandostatin LAR Depot, which is used for treating acromegaly and certain types of diarrhea related to tumors [3][4]. - This approval marks VTRS' first injectable product utilizing microsphere technology and is the fourth injectable approval for the company in 2025, enhancing its generics portfolio with complex, high-value products [4]. - The FDA has accepted VTRS' new drug application (NDA) for a low-dose estrogen weekly contraceptive patch, aimed at women with a BMI below 30 kg/m², with a target action date set for July 30, 2026 [5][6]. - The patch delivers approximately 150 mcg of norelgestromin and 17.5 mcg of ethinyl estradiol daily, representing a new option for women seeking lower estrogen doses [6][7]. - The FDA has cleared an investigational new drug (IND) application for MR-146, a gene therapy candidate for neurotrophic keratopathy, with a phase I/II clinical trial planned for the first half of 2026 [8][9]. - Viatris has also received acceptance for its Japanese NDA for pitolisant in obstructive sleep apnea syndrome (OSAS), with plans to submit a separate NDA for narcolepsy by year-end [10][11]. Company Performance - Viatris has demonstrated strong performance over the past six months, with shares increasing by 34.6%, compared to the industry growth of 6.1% during the same period [12]. - The company's expansion in Emerging Markets and robust growth in Greater China are positively impacting sales, with new drug approvals expected to further enhance its portfolio [13].

Key Takeaways U.S. pharma entered a rebound in 2025, with a $370B domestic investment pledge reshaping the industry. Tariff threats and MFN pricing deals pushed firms like Eli Lilly to expand U.S. manufacturing capacity. ETFs such as IHE offer diversified exposure to pharma's growth while reducing single-stock risks. The U.S. pharmaceutical industry underwent a historic, policy-driven transformation in 2025. After a period of post-pandemic cooling, the industry demonstrated stark improvement, ignited by a ...

Core Viewpoint - Merck & Co. Inc. will not exercise its option for Evaxion A/S's Gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek another licensing partner [1][2]. Group 1: Company Developments - Evaxion's Gonorrhea vaccine candidate EVX-B2 has shown protective effects against the bacteria in preclinical studies, yet no vaccine has been approved for Gonorrhea despite over 80 million infections annually [2]. - Evaxion's CEO, Helen Tayton-Martin, stated that the decision by Merck does not affect the company's cash runway, which extends to the second half of 2027 [2]. - Merck's option was specifically for the protein-based version of EVX-B2, while Evaxion is also developing an mRNA version in collaboration with Afrigen Biologics [3]. Group 2: Financial Aspects - Evaxion received a cash payment of $7.5 million from Merck and is eligible for future milestone payments of up to $592 million, along with royalties on net sales for the EVX-B3 vaccine [4]. - Merck will take full responsibility for the further development and associated costs of the EVX-B3 vaccine [4]. Group 3: Market Reaction - Following the news, Evaxion's stock (EVAX) experienced a decline of 14.61%, trading at $4.91 [5].